Final NHS ‘no’ for obesity pill Mysimba
An appeal to get NHS funding for Mysimba as a means for controlling weight has failed, with cost-regulators publishing final guidelines rejecting the drug.
Read More
Tag: Mysimba
NICE bars obesity pill from routine NHS use
Cost regulators for NHS treatments in England and Wales are standing by their position that Orexigen’s weight loss pill Mysimba can not be recommended as a cost-effective treatment option.
Read More
Draft NICE rejection for Orexigen’s weight-loss pill
The National Institute for Health and Care Excellence has published draft guidelines turning down Orexigen’s weight loss pill Mysimba for routine NHS use.
Read More
- CERo reports encouraging early data from phase 1 trial of CER‑1236
- ENA Respiratory begins dosing in phase 2 study of INNA‑051 nasal spray
- Argo Biopharma doses first patient in phase 2b trial of BW‑20829
- Akari files new patent and advances second ADC targeting CEACAM5
- BioMed X launches kidney disease project in partnership with the government of Barbados
